| Literature DB >> 29289982 |
Hongli Zhao1,2, Yanqiu Zhao1, Yingmei Zhang3, Jinxiao Hou1, Huiyuan Yang1, Fenglin Cao3, Yiju Yang4, Wenyi Hou1, Jiayue Sun1, Bo Jin1, Jinyue Fu1, Haitao Li1, Ping Wang1,5, Fei Ge1, Jin Zhou6,7.
Abstract
Early death (ED) remains the most critical issue in the current care of patients with acute promyelocytic leukemia (APL). Very limited data are available regarding ED in patients with relapsed APL. In this retrospective study, 285 de novo and 79 relapsed patients were included. All patients received single-agent arsenic trioxide as induction therapy. The differences in baseline clinical features, incidence, causes, and prognostic factors of ED were compared between the two patient cohorts. The relapse cohort exhibited a better overall condition than the de novo cohort upon hospital admission. The ED rate in the relapsed patients (24.1%) was somewhat higher than that in the de novo patients (17.9%), although the difference was not significant (P = 0.219). For both cohorts, hemorrhage was the main cause of ED, followed by differentiation syndrome, infection, and other causes. Increased serum creatinine level, older age, male sex, white blood cell (WBC) count > 10 × 109/L, and fibrinogen < 1 g/L were independently risk factors for ED in the de novo patients, whereas WBC count > 10 × 109/L, elevated serum uric acid level, and D-dimer > 4 mg/L were independent risk factors for ED in the relapsed patients. These data furnish clinically relevant information that might be useful for designing more appropriate risk-adapted treatment protocols aimed at reducing ED rate in patients with relapsed APL.Entities:
Keywords: Acute promyelocytic leukemia; Arsenic trioxide; Early death; Relapse; Risk factor
Mesh:
Year: 2017 PMID: 29289982 DOI: 10.1007/s00277-017-3216-2
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673